Ipamorelin vs Hexarelin: GHRP Selectivity Research Comparison
Compare ipamorelin and hexarelin — two GHRPs at opposite ends of the selectivity spectrum — across GH pulse amplitude, prolactin/cortisol release, and tachyphylaxis profile.
Ipamorelin and hexarelin sit at opposite ends of the GHRP selectivity spectrum. Hexarelin is the most potent GH secretagogue in the class but with the largest off-target hormone release; ipamorelin is the cleanest GHRP but with a more modest pulse. This comparison summarises the published literature relevant to laboratory research.
At-a-glance comparison
| Attribute | Ipamorelin | Hexarelin | |---|---|---| | Class | Pentapeptide GHRP (GHS-R agonist) | Hexapeptide GHRP (GHS-R agonist) | | GH pulse potency (published) | Moderate | High — among the most potent GHRPs | | Prolactin release | Minimal (cleanest GHRP) | Notable elevation reported | | Cortisol / ACTH release | Minimal | Notable elevation reported | | Tachyphylaxis (receptor desensitisation) | Low at typical research doses | Reported with chronic dosing | | Cardiac CD36 binding (published) | Not characterised as primary | Characterised — cardioprotection research | | Typical research dosing | 100-300 mcg per administration | 100-200 mcg per administration |
Mechanism
Both bind GHS-R 1a on pituitary somatotrophs. Hexarelin has additional reported binding at cardiac CD36 — the basis for a small but distinct cardioprotection research literature that ipamorelin does not share.
Published research highlights
- Ipamorelin (Novo Nordisk, 1998) was specifically developed to retain GHRP potency while eliminating prolactin and cortisol release.
- Hexarelin is most-cited for cardioprotective endpoints in ischemia-reperfusion models via CD36 binding — a unique feature in the GHRP class.
- Tachyphylaxis with chronic hexarelin dosing is well-documented in published research; ipamorelin shows minimal tachyphylaxis at typical research doses.
Selecting between them in research
- For clean GH-axis research without confounding hormone elevations: ipamorelin.
- For cardiac CD36 / cardioprotection research: hexarelin (no other GHRP substitutes).
- For maximum GH pulse amplitude with off-target tolerance: hexarelin.
Combination research
Both are routinely combined with GHRH analogs (CJC-1295, sermorelin, tesamorelin) for additive pulse amplitude. Ipamorelin is the preferred GHRP for long-running combination protocols because of its low tachyphylaxis and clean hormone profile.
Frequently asked research questions
Why is ipamorelin called the "cleanest" GHRP? Published receptor-binding and hormone-release data show minimal prolactin and cortisol elevation compared with GHRP-2, GHRP-6, and hexarelin.
Is hexarelin still relevant if ipamorelin is cleaner? Yes — hexarelin's cardiac CD36 binding gives it a research niche (cardioprotection) that ipamorelin does not occupy.
How do they compare to GHRP-2 and GHRP-6? Ipamorelin is cleaner than both; hexarelin is more potent than both at GH release with more off-target activity.
Related research
- CJC-1295 vs Ipamorelin research comparison
- GHRP-2 vs GHRP-6 research comparison
- GHRP receptor pharmacology overview
Related Research Articles
What is BPC-157? A Research Primer
A comprehensive research primer on BPC-157 (Body Protection Compound-157) — a pentadecapeptide derived from human gastric juice. Covers origins, mechanism of action, tendon and gut healing research, angiogenesis, and CNS research findings.
Peptide Reconstitution 101
A complete step-by-step guide to reconstituting lyophilized research peptides. Covers bacteriostatic water vs sterile water, reconstitution math, injection technique, storage after reconstitution, and common mistakes to avoid.
GHK-Cu Research Overview
A copper-binding tripeptide endogenous to human plasma, studied extensively in wound healing, collagen synthesis, antioxidant defense, and gene expression regulation within cellular research models.